Seminar Invitation: Pitfalls for SMEs in protecting and claiming incentives for new developments

Presented by:

  • Joe Seisdedos (Wrays)Wrays
  • Bill Charlton (UHY Haines Norton)
  • Michael Oon (Swanson Reed)

Join Swanson Reed, UHY Haines Norton and Wrays for a practical workshop that will focus on the problems that every day companies face in protecting, and claiming incentives for their new products.

You will hear from three industry experts on a range of topics, including tax issues, R&D tax incentives and patent protection.

On conclusion of the presentation, participants will have an opportunity to ask the panel any specific questions in a friendly and constructive forum.

 

Time Presentation Presenter
7:00am – 7:30am: Session 1: Protecting Intellectual Property (IP) Joe Seisdedos
7:30am – 8:00am: Session 2: IP & Relevant Tax Considerations Bill Charlton
8:00am – 8:30am: Session 3: R&D Tax Incentives Michael Oon
8:30am – 9:00am: Session 4: Panel Q&A and Networking Opportunity

 

Joe Seisdedos Bill Charlton Michael Oon
Joe_seisdedos Bill-Charlton Michael-Oon
 View Joe’s bio  View Bill’s bio  View Michael’s bio

Brisbane R&D Tax Seminar:


View Larger Map

Wednesday, 18th June 2014
7am – 9am
Swanson Reed Boardroom
Level 11, 42-60 Albert St
Brisbane, 4000

Cost: Free!
Register Before:
 Friday 13th June

 

Full attendance at this workshop will yield 2 CPE hours towards the Tax Practitioners Board’s (TPB) CPE requirements.

Contact Amy Nolan for more information:

Ph: 07 3221 1499
Mob: 0435 713 493

Are you Eligible to claim R&D? Take our R&D Eligibility Survey and find out.

Latest News

Imugene Ltd receives $6.5M R&D Tax Offset Refund

Melbourne-based Imugene Ltd announced in January 2022 the receipt of the company’s FY21 R&D Tax Offset refund of $6,541,921. The company has noted that the funds will support its commercial and clinical milestones, several of which have progressed in recent months, including: Granting of additional patents for the company’s HER-Vaxx Immunotherapy in China and South Korea; Completion of Phase 1a trial of immunotherapy PD1-Vaxx; US Food and Drug Administration (FDA) consent for clinical trials for its oncology treatments. In recent […]

ATO Release Finalised Tax Tuling TR 2021/5 (At Risk Rule)

Under SECT 355.405 ITAA97, an entity cannot claim R&D expenditure in situations where: (a) when an entity incurs R&D expenditure, consideration has been received, or was reasonably expected to be received: o as a direct or indirect result of the expenditure being incurred; and o regardless of the results of the activities on which the expenditure is incurred; and (b) that consideration is equal to or greater than the expenditure. The spirit of this provision is to ensure companies only […]

    Email this job